Clinical Trial Detail

NCT ID NCT03045328
Title Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Steven E. Coutre
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Age Groups: adult senior

No variant requirements are available.